A. Yoshizawa

发表

Alanine-Serine-Cysteine Transporter 2 Inhibition Suppresses Prostate Cancer Cell Growth In Vitro

Motoshi Suzuki, M. Sumitomo, K. Zennami, 2022, Journal of clinical medicine.

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

K. Takahara, R. Shiroki, H. Azuma, 2022, Cancers.

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

K. Takahara, R. Shiroki, H. Azuma, 2022, Clinical and translational radiation oncology.

Recurrent intussusception due to multiple intestinal metastases from lung adenocarcinoma

M. Kuroda, I. Uyama, Harunobu Sato, 2016 .

Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7–positive prostate cancer cells

Motoshi Suzuki, M. Sumitomo, N. Fukami, 2020, Prostate international.

Clinical Outcomes Associated with Robot-Assisted Radical Prostatectomy (RARP) Using the Extraperitoneal Approach in Japanese Men

Masahiro Ito, N. Fukami, K. Fukaya, 2018 .

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

T. Adachi, S. Egawa, K. Takahara, 2022, BJU international.

Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.

K. Takahara, R. Shiroki, Shunsuke Tsuzuki, 2023, Cancer medicine.

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.

K. Takahara, R. Shiroki, H. Azuma, 2023, Clinical genitourinary cancer.

Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.

R. Shiroki, K. Komura, T. Inamoto, 2024, Targeted oncology.